| abstract |
The present invention relates to a polyplex for use in the treatment of castration-resistant prostate cancer (CRPC) comprising double-stranded RNA (dsRNA) and a polymeric conjugate, said polymeric conjugate consisting of a linear polyethyleneimine (LPE1). ), one or more polyethylene glycol (PEG) moieties, one or more linkers, and one or more targeting moieties, said LPE1 being covalently bound to one or more PEG moieties and each of said PEG moieties being conjugated by one or more moieties. intermediate of any linker to any targeting moiety, each of said targeting moieties being capable of binding to a cancer antigen, and said cancer antigen being a prostate surface membrane antigen (PSMA). The present invention also relates to a pharmaceutical composition for use in the treatment of CRPC. |